Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason B Cross

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
RSC Medicinal Chemistry|September 19, 2025
Allosteric targeting of RIPK1: discovery of novel inhibitors <i>via</i> parallel virtual screening and structure-guided optimizationR S K Vijayan, Matthew M Hamilton, Dana E Pfaffinger, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
ACS Medicinal Chemistry Letters|February 18, 2026
Structure-Guided Development of NRAS G12D Inhibitors Based on a 5‑Azaindole CoreJoshua B Cox, Vinay Nair, Pijus Mandal, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2017
Structure-based discovery of LpxC inhibitorsJing Zhang, Audrey Chan, Blaise Lippa, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Nature|September 16, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLCJacqulyne P Robichaux, Xiuning Le, R S K Vijayan, et al.
Journal of Medicinal Chemistry|July 22, 2021
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) ApoenzymeMatthew M Hamilton, Faika Mseeh, Timothy J McAfoos, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
RSC Medicinal Chemistry|September 19, 2025
Allosteric targeting of RIPK1: discovery of novel inhibitors <i>via</i> parallel virtual screening and structure-guided optimizationR S K Vijayan, Matthew M Hamilton, Dana E Pfaffinger, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
ACS Medicinal Chemistry Letters|February 18, 2026
Structure-Guided Development of NRAS G12D Inhibitors Based on a 5‑Azaindole CoreJoshua B Cox, Vinay Nair, Pijus Mandal, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2017
Structure-based discovery of LpxC inhibitorsJing Zhang, Audrey Chan, Blaise Lippa, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Nature|September 16, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLCJacqulyne P Robichaux, Xiuning Le, R S K Vijayan, et al.
Journal of Medicinal Chemistry|July 22, 2021
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) ApoenzymeMatthew M Hamilton, Faika Mseeh, Timothy J McAfoos, et al.
Pageof 4